Open access journal of the Ferrata-Storti Foundation, a non-profit organization
Erratum

Erratum to: “Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial”

Department of Hematology, University Hospital Center of Lille, Lille
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Department of Medicine, Korea University, Seoul
Service d’Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402, Poitiers Cedex
Department of Hematology, University Hospital Hotel-Dieu, Nantes
Dipartimento di Scienze Mediche e Chirurgiche, Universita di Bologna, Bologna
Department of Internal Medicine V, University of Heidelberg, Heidelberg
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Sanofi, Vitry
Sanofi, Cambridge, MA
Sanofi R&D, Vitry-sur-Seine
Sanofi, Cambridge, MA
Istinye University Ankara Liv Hospital, Ankara, Turkey
Department of Hematology, University Hospital Center of Lille, Lille, France; French National Academy of Medicine, Paris
Vol. 111 No. 7 (2026): July, 2026 https://doi.org/10.3324/haematol.2026.289422

An issue was identified with the labeling of the IsaVRd and VRd arms in Figure 3A, B.1 The revised and corrected Figure 3 is shown below.

Figure 3.Quality of life as measured by EORTC-QLQ-C30 in the frail and non-frail subgroups. (A) Frail subgroup. (B) Non-frail subgroup. d: dexamethasone; EORTC-QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30; EOT: end of treatment; Fu: follow-up; Isa: isatuximab; R: lenalidomide; V: bortezomib.

Footnotes

  • Received February 24, 2026
  • Accepted February 24, 2026

Correspondence

S. Manier salomon.manier@chu-lille.fr

References

  1. Manier S, Dimopoulos M-A, Leleu XP. Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplantineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial. Haematologica. 2025; 110(9):2139-2150. Google Scholar

Figures & Tables

Article Information

Vol. 111 No. 7 (2026): July, 2026 : Erratum
 
DOI
https://doi.org/10.3324/haematol.2026.289422
 
Published
2026-07-01
Published By
Ferrata Storti Foundation, Pavia, Italy
Print ISSN
0390-6078
Online ISSN
1592-8721
 
Copyright & Usage
Copyright (c) 2026 Ferrata Storti Foundation
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Article Usage

Online Views
1
PDF Downloads
0
No Data
PlumX
Navigate
For Authors
For Reviewers
For Advertisers
Education
Privacy
More
Copyright © 2026 by the Ferrata Storti Foundation | Web design ￫ | Development ￫
ISSN 0390-6078 print | ISSN 1592-8721 online